Temodal gains additional use

The licensed indications for the antineoplastic agent Temodal (temozolomide) have been extended to include the treatment of patients with newly diagnosed glioblastoma multiforme.

Temodal is administered orally together with focal radiotherapy, followed by up to six cycles as monotherapy.

A clinical trial involving 573 patients with newly diagnosed glioblastoma multiforme randomised to receive temozolomide plus radiotherapy or radiotherapy alone showed a significant improvement in survival in the radiotherapy plus temozolomide group compared with the radiotherapy-only group.

Further information: Schering-Plough Ltd, Schering-Plough House, Shire Park, Welwyn Garden City, Herts AL7 1TW. Tel: (01707) 363636.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases